Immunotherapy duo plus radiation shows promise in early lung cancer trial
NCT ID NCT04013542
First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This early-phase study tested two immunotherapy drugs (ipilimumab and nivolumab) combined with radiation in 21 people with stage II or III non-small cell lung cancer that could not be removed by surgery. The goal was to see if the combination is safe and helps shrink tumors. Participants received the drugs and radiation, and researchers monitored side effects and cancer response. This approach aims to control the disease rather than cure it, as ongoing management is typically needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.